We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Medicine & public health

Search Results

Showing 1-20 of 179 results

  1. Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab

    Alzheimer’s disease (AD) is a neurodegenerative condition that causes cognitive decline, memory loss, and reduced personal autonomy. The pathology of...

    Taha Basit Ameen, Syeda Naveera Kashif, ... Abdul Raheem in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
    Article Open access 14 June 2024

  2. Donanemab in Japanese Patients with Early Alzheimer’s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial

    Introduction

    Donanemab, a monoclonal antibody directed against an insoluble, modified, N-terminal truncated form of amyloid beta, demonstrated...

    Shoichiro Sato, Naohisa Hatakeyama, ... John R. Sims in Neurology and Therapy
    Article Open access 06 April 2024

  3. Alzheimerdemenz mit Donanemab gebremst

    Thomas Müller in CME
    Article 14 December 2023

  5. ‘Time Saved’ As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

    In Alzheimer’s disease (AD) clinical trials, disease-modifying therapies are expected to slow the rate of disease progression. Treatment effects are...

    S. P. Dickson, Alette M. Wessels, ... S. Hendrix in The Journal of Prevention of Alzheimer's Disease
    Article Open access 03 May 2023

  8. Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging

    Background

    Donanemab (LY3002813) is an IgG1 antibody directed at an N-terminal pyroglutamate of amyloid beta epitope that is present only in brain...

    S. L. Lowe, C. Duggan Evans, ... John R. Sims in The Journal of Prevention of Alzheimer's Disease
    Article Open access 21 September 2021

  10. Kausale Alzheimertherapie

    Around 130,000 Austrians suffer from dementia, predominantly Alzheimer’s disease (AD), which is projected to double by 2050. An additional...

    Peter Dal-Bianco in psychopraxis. neuropraxis
    Article 18 April 2024

  12. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis

    Background

    Recent clinical trials of anti-Aβ monoclonal antibodies (mAbs) in the treatment of early Alzheimer’s disease (AD) have produced encouraging...

    Yue Qiao, Jian Gu, ... Ying Ma in CNS Drugs
    Article 01 March 2024

  13. Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer’s disease

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a complex pathogenesis. Senile plaques composed of the amyloid-β (Aβ)...

    Yan Lian, Yu-Juan Jia, ... Yan-Jiang Wang in Molecular Psychiatry
    Article 24 November 2023

  14. Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion

    Introduction

    Alzheimer’s disease (AD) is the most common cause of dementia worldwide, making it a major public health issue. Anti-amyloid and anti-tau...

    Arthur Esquer, Frédéric Blanc, Nicolas Collongues in Neurology and Therapy
    Article Open access 09 October 2023

  15. Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010–2020

    Alzheimer’s disease (AD) is the most common form of dementia. There is currently no cure, and the available pharmacological treatment focuses on...

    N. Navarro-Gómez, M. Valdes-Gonzalez, ... Gabino Garrido in The Journal of Prevention of Alzheimer's Disease
    Article 05 January 2023

  16. Kausale Therapie der Alzheimer-Krankheit: Amyloidantikörper

    Background

    Alzheimerʼs disease (AD) is the most common cause of dementia. The number of people affected will increase dramatically in the coming...

    Matthias Pawlowski, Tobias Warnecke in Die Innere Medizin
    Article 15 March 2022

  17. The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report

    BACKGROUND: Aducanumab (ADUHELM™) was approved for the treatment of Alzheimer’s disease (AD) in the US. This approval was supported by an effect on...

    Julien Delrieu, R. J. Bateman, ... J. Cummings in The Journal of Prevention of Alzheimer's Disease
    Article Open access 16 May 2022

  18. Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease

    One of the central aims in Alzheimer’s disease (AD) research is the identification of clinically relevant drug targets. A plethora of potential...

    Thomas A. Bayer in Molecular Psychiatry
    Article Open access 08 December 2021

  19. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer’s Disease Treated with Anti-Amyloid Beta Therapy

    Amyloid-related imaging abnormalities (ARIA) are adverse events reported in Alzheimer’s disease trials of anti-amyloid beta (Aβ) therapies. This...

    Jerome Barakos, D. Purcell, ... E. Vijverberg in The Journal of Prevention of Alzheimer's Disease
    Article Open access 02 February 2022
Did you find what you were looking for? Share feedback.